Beijing Hotgen Biotech (688068) Fundamentals 2026 — Revenue Analysis | SniperIQ
Beijing Hotgen Biotech (688068) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥11.4B, trading at ¥123.22 on the SHH. This SniperIQ fundamentals page covers Beijing Hotgen Biotech's valuation, profitability (net margin -60.8%), revenue (¥404M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Beijing Hotgen Biotech's market cap?
Beijing Hotgen Biotech (688068) has a market capitalization of approximately ¥11.4B, trading at ¥123.22 on the SHH. Market cap moves with the live share price.
What is Beijing Hotgen Biotech's P/E ratio?
Beijing Hotgen Biotech's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Beijing Hotgen Biotech?
Beijing Hotgen Biotech runs a net profit margin of -60.8%, a gross margin of 53.8%, and an operating margin of -82.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Beijing Hotgen Biotech generate?
Beijing Hotgen Biotech reported revenue of ¥404M for fiscal year 2025, with net income of -¥216M and earnings per share (EPS) of -2.24. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Beijing Hotgen Biotech pay a dividend?
Beijing Hotgen Biotech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Beijing Hotgen Biotech financially healthy?
Beijing Hotgen Biotech carries a debt-to-equity ratio of 0.01x and a current ratio of 6.74x, with a market beta of 0.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Beijing Hotgen Biotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beijing Hotgen Biotech (688068) the key facts are: market cap ¥11.4B, revenue ¥404M, 52-week range 73.44-262.22. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Beijing Hotgen Biotech's full fundamentals live
Get Beijing Hotgen Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.